ASSOCIATION OF BETA-ADRENOREACTIVITY OF ERYTHROCYTE MEMBRANES WITH THE SEVERITY OF CHRONIC HEART FAILURE IN PATIENTS WITH CORONARY HEART DISEASE

Highlights

Beta-adrenoreactivity of erythrocyte membranes (beta-ARM) is an indirect indicator of the activity of the sympathoadrenal system and can act as a marker of the severity of heart failure. In patients with chronic coronary artery disease, higher beta-ARM values are associated with a lower left ventricular ejection fraction. Beta-ARM is elevated in people who have suffered a prior myocardial infarction.

Abstract

Aim. To assess the relationship between erythrocyte membrane beta-adrenoreactivity (beta-ARM) and the level of catecholamines in the blood with the functional state of the myocardium in patients with chronic heart failure (CHF) of ischemic origin.

Methods. The study included 116 patients with chronic ischemic heart disease, of which 56.9% of patients had postinfarction cardiosclerosis (PICS). In the sample, functional class (FC) I CHF was present in 10.3% of patients, FC II in 56.0% of patients, and FC III in 33.6% of patients. Based on echocardiography data, CHF with preserved left ventricular ejection fraction (LVEF≥50%) was detected in 78.4% of patients, in 7.8% of patients with reduced LVEF<40%, and in 13.8% of patients with mid‐range LVEF 40–49%. The levels of adrenaline and norepinephrine in the blood plasma were determined using the ELISA kits. Beta-ARM was assessed using the Beta-ARM-Agate kit in accordance with the manufacturer's protocol.

Results. The study sample revealed an inverse relationship between beta-ARM and LVEF (r = –0.318, p = 0.001), as well as a direct correlation with the LV sphericity index (r = 0.331, p = 0.001). An inverse linear relationship was found between the LVEF and the level of adrenaline (r = –0.287, p = 0.010) and norepinephrine (r = –0.418, p < 0.001). Patients with PICS had higher values of beta-ARM (29.7% (19.2; 39.1) vs 21.4% (14.8; 26.7), p = 0.004) and norepinephrine (30.5% (24.3; 41.8) vs 26.9% (19.6; 30.1), p = 0.042) compared with patients without PICS. Groups with different CHF FCs had comparable levels of catecholamines, but differed in beta-ARM (p = 0.029): 22.8% (19.5; 29.2) with FC I, 21.4% (14.8; 28.4) with FC II, 30.1% (19.4; 40.1) with FC III. There was a tendency towards differences in beta-ARM between groups in LVEF (p = 0.053).

Conclusion. Thus, the results of the study revealed an association between beta-ARM and norepinephrine levels with systolic myocardial dysfunction. Higher values of beta-ARM and norepinephrine correlate with lower LVEF and indicate an unfavorable course of heart failure.

1. Obrezan A.G., Kulikov N.V. Neuro-humoral disbalance in chronic heart failure: classic and modern perspectives. Russian Journal of Cardiology. 2017; 9: 83-92. doi:10.15829/1560-4071-2017-9-83-92(In Russian)

2. Brodde O.E., Michel M.C. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev. 1999; 51: 651-690.

3. Myagmar B.E., Flynn J.M., Cowley P.M., Swigart P.M., Montgomery M.D., Thai K., Nair D., Gupta R., Deng D.X., Hosoda C., Melov S., Baker A.J., Simpson P.C. Adrenergic receptors in individual ventricular myocytes: the beta-1 and alpha-1b are in all cells, the alpha-1a is in a subpopulation, and the beta-2 and beta-3 are mostly absent. Circ. Res. 2017; 120: 1103-1115. doi:10.1161/CIRCRESAHA.117.310520

4. Ranade K., Jorgenson E., Sheu W.H.-H., Pei D., Hsiung C.A., Chiang F., Chen Y.D., Pratt R., Olshen R.A., Curb D., Cox D.R., Botstein D., Risch N. A Polymorphism in the β1 Adrenergic Receptor Is Associated with Resting Heart Rate. Am J Hum Genet. 2002; 70 (4): 935-942. doi:10.1086/339621

5. Zhu W., Woo A.Y., Zhang Y., Cao C.M., Xiao R.P. β-adrenergic receptor subtype signaling in the heart: from bench to the bedside. Curr. Top. Membr. 2011; 67: 191-204. doi:10.1016/B978-0-12-384921-2.00009-4

6. Ungerer M., Böhm M., Elce J.S., Erdmann E., Lohse M.J. Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. Circulation. 1993; 87 (2): 454-463. doi:10.1161/01.cir.87.2.454

7. Afanasiev S.A., Lishmanov Ju.B., Kondratiev B.Ju., Chernjavskij A.M., Karpov R.S. Farmakologicheskie dokazatel'stva narushenija adrenoreaktivnosti miokarda v uslovijah hronicheskoj koronarnoj ishemii. Fiziologija cheloveka. 1997; 23 (5): 58-62. (In Russian)

8. Ripp T.M., Rebrova T.Y., Mordovin V.F., Afanasiev S.A., Pekarsky S.E., Semke G.V., Falkovskaya A.Yu., Lichikaki V.A., Tsymbalyuk E.V. Criteria for selecting patients with resistant hypertension for a renal sympathetic denervation. Terapevticheskii arkhiv. 2016; 88 (8): 14-18. doi:10.17116/terarkh201688814-18 (In Russian)

9. Strjuk R.I., Dlusskaja I.G. Adrenoreaktivnost' i serdechno-sosudistaja sistema. Moscow: Medicina; 2003. (In Russian)

10. Atabekov T.A., Batalov R.E., Rebrova T.Y., Krivolapov S.N., Muslimova E.F., Khlynin M.S., Afanasiev S.A., Popov S.V. Ventricular tachycardia incidence and erythrocyte membranes β-adrenoreactivity in patients with implanted cardioverter-defibrillator. Pacing and Clinical Electrophysiology. 2022; 45 (4): 452-460. doi:10.1111/pace.14479

11. Garganeeva A.A., Aleksandrenko V.A., Kuzheleva E.A., Rebrova T.Yu. Beta-adrenergic reactivity of erythrocytes and the progression of heart failure in patients after myocardial infarction. Russian Journal of Cardiology. 2020; 25 (1): 20-25. doi:10.15829/1560-4071-2020-1-3407 (In Russian)

12. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G.F., Coats A.J.S., Falk V., González-Juanatey J.R., Harjola V.P., Jankowska E.A., Jessup M., Linde C., Nihoyannopoulos P., Parissis J.T., Pieske B., Riley J.P., Rosano G.M.C., Ruilope L.M., Ruschitzka F., Rutten F.H., van der Meer P.; ESC Scientific Document Group.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2016; 37: 2129-2200. doi:10.1093/eurheartj/ehw128

13. de Lucia C., Eguchi A., Koch W.J. New Insights in Cardiac β-Adrenergic Signaling During Heart Failure and Aging. Front. Pharmacol. 2018; 9: 904. doi:10.3389/fphar.2018.00904

14. Agüero J., Almenar L., Montó F., Oliver E., Sánchez-Lázaro I., Vicente D., Martínez-Dolz L., D'Ocon P., Rueda J., Salvador A. Myocardial G protein receptor-coupled kinase expression correlates with functional parameters and clinical severity in advanced heart failure. J Card Fail. 2012; 18 (1): 53-61. doi:10.1016/j.cardfail.2011.10.008

15. Doughty R.N., MacMahon S., Sharpe N. Beta-blockers in heart failure: Promising or proved? J. Amer. Coll. Cardiology. 1994; 23 (3): 814-21. doi: 10.1016/0735-1097(94)90773-0.

16. Bulashova O.V., Oslopov V.N., Khazova E.V., Kirilova Y.A. Adrenoreactivity in patients with chronic heart failure. Practical medicine. 2011; 52 (4): 72-74. (In Russian)

17. Hartupee J., Mann D.L. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 2017; 14 (1): 30-38. doi:10.1038/nrcardio.2016.163

18. Muslimova E., Rebrova T., Kondratieva D., Korepanov V., Sonduev E., Kozlov B., Afanasiev S. Expression of the β1-adrenergic receptor (ADRB1) gene in the myocardium and β-adrenergic reactivity of the body in patients with a history of myocardium infraction. Gene. 2022; 844: 146820. doi:10.1016/j.gene.2022.146820